ANAPTYSBIO, INC. Treasury Stock Acquired, Average Cost Per Share
ANAPTYSBIO, INC. (ANAB) reported Treasury Stock Acquired, Average Cost Per Share of $33.83 per share for the 3-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:TreasuryStockAcquiredAverageCostPerShare · last filed 2026-03-03
- ANAPTYSBIO, INC. treasury stock acquired, average cost per share for the quarter ending 2025-12-31 was $33.83.
- ANAPTYSBIO, INC. treasury stock acquired, average cost per share for the quarter ending 2025-09-30 was $19.83.
- ANAPTYSBIO, INC. treasury stock acquired, average cost per share for the quarter ending 2025-06-30 was $19.58.
- ANAPTYSBIO, INC. treasury stock acquired, average cost per share for the quarter ending 2025-03-31 was $18.35.
| Period end | Treasury Stock Acquired, Average Cost Per Share 3 month |
|---|---|
| 2025-12-31 | $33.83 10-K · filed 2026-03-03 |
| 2025-09-30 | $19.83 10-K · filed 2026-03-03 |
| 2025-06-30 | $19.58 10-K · filed 2026-03-03 |
| 2025-03-31 | $18.35 10-K · filed 2026-03-03 |
| 2023-06-30 | $21.59 10-K · filed 2025-02-27 |
| 2023-03-31 | $24.19 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |